AEterna Zentaris Seeks Partner for BPH Treatment

TORONTO, Oct 2 (Reuters) - A new management team at AEterna Zentaris (AEZ.TO: Quote, Profile, Research) (AEZS.O: Quote, Profile, Research) put its stamp on the Canadian biotechnology company on Tuesday, unveiling a strategic plan that includes commercialization of its key Cetrorelix drug and the sale of some non-core assets.
MORE ON THIS TOPIC